Pfizer’s recent decision to discontinue the development of its twice-daily weight loss pill, danuglipron, highlights the ongoing challenges faced by pharmaceutical companies in creating effective and safe treatments for obesity. While obese patients in clinical trials experienced significant weight loss with the drug, the high rates of adverse side effects were a cause for concern.
0 Comments
The highly publicized “Take Care of Maya” trial concluded recently with a staggering $261 million verdict in compensatory and punitive damages for the Kowalski family. The jury held Johns Hopkins All Children’s Hospital of Florida responsible for various claims, including Beata Kowalski’s wrongful death by suicide, infliction of emotional distress, and false imprisonment and battery.
0 Comments